Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"AcedrA BioPharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo\u00ae (Ibalizumab-uiyk) in the Middle East and North Africa Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"TAIWAN","productType":"Large molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by TaiMed Biologics

    Menu

    TaiMed Biologics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TaiMed Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region

              Details:

              Under the terms of this agreement, AcedrA will register, promote and commercialize Trogarzo (Ibalizumab-uiyk), a CD4-directed post-attachment HIV-1 inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, in the MENA region.

              Lead Product(s): Ibalisumab

              Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: AcedrA BioPharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 18, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TaiMed Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment

              Details:

              TMB-365/380 monoclonal antibodies is an ultra-long-acting new drug combination, which is investigated for the treatment of human immunodeficiency virus infection.

              Lead Product(s): TMB-365,TMB-380

              Therapeutic Area: Infections and Infectious Diseases Product Name: TMB-365

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY